New type of treatment for Uterine Fibroids
Clinical Trial Seeking Participants
IRB 7812 (PI: Jeffrey Jensen, M.D., M.P.H.)
The Women’s Health Research Unit is conducting a study to investigate a new type of treatment for uterine fibroids and heavy uterine bleeding.
Open to Enrollment
Why is this study being done?
The study drug is a new drug that is being developed for the treatment of endometriosis (a condition in which the tissue that behaves like the cells lining the uterus grows in other areas of the body) and uterine fibroids (noncancerous tumors that develop in the uterus). The study drug is very similar to a natural hormone that is made by brain cells. The study drug partially reduces the production of the female hormone estrogen in the ovaries.
The purpose of this study is to determine:
- What dosage of study drug safely reduces the amount of blood loss during the menstrual cycle
- What dosage of study drug safely reduces the size of uterine fibroids
- To analyze amount of blood loss from the beginning of study participation until the end
- Changes of hemoglobin concentration from beginning of study participation until the end
Who is eligible to participate?
- Pre-menopausal women at least 20 years old
- Are in good general health
- Have regular menstrual periods (24-35 days)
- Diagnosis of uterine fibroids
You must not be using a hormonal form of birth control and are willing to use two forms of non-hormonal contraception. You do not have to be sexually active to participate in this research study.
What is the compensation for this study?
Qualified participants will receive, at no cost:
- Well woman exams
- Compensation for time and travel of up to $900 for the 9 month period of the study